Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) CFO Mark J. Vignola sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $11.00, for a total value of $110,000.00. Following the completion of the sale, the chief financial officer now owns 91,940 shares of the company’s stock, valued at approximately $1,011,340. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Terns Pharmaceuticals Trading Down 5.8 %
Shares of NASDAQ:TERN opened at $8.96 on Friday. Terns Pharmaceuticals, Inc. has a 12-month low of $3.26 and a 12-month high of $11.40. The business’s fifty day simple moving average is $8.07 and its 200-day simple moving average is $6.94.
Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) last posted its earnings results on Monday, August 5th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.04. As a group, equities analysts anticipate that Terns Pharmaceuticals, Inc. will post -1.3 earnings per share for the current year.
Institutional Investors Weigh In On Terns Pharmaceuticals
Wall Street Analyst Weigh In
TERN has been the subject of several research reports. BMO Capital Markets reiterated an “outperform” rating and issued a $19.00 target price on shares of Terns Pharmaceuticals in a report on Tuesday, August 6th. JMP Securities upped their price objective on shares of Terns Pharmaceuticals from $15.00 to $20.00 and gave the stock a “market outperform” rating in a research note on Tuesday, September 10th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.50.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
See Also
- Five stocks we like better than Terns Pharmaceuticals
- 5 Top Rated Dividend Stocks to Consider
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- What is a Dividend King?
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- Stock Average Calculator
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.